Skip to content
Not yet recruitingPhase 3

A Study Comparing Oral Ketamine With Oral Midazolam for the Treatment of Major Depressive Episodes

NCT07839338 · KOMET · Jawaharlal Institute of Postgraduate Medical Education & Research

Closed to entry
Status
Not accepting participants
Phase 3
Phase
220
Target enrolment
5
Study sites
Outside the US

What it is testing

Summary

Patients with depression are acutely distressed, often suicidal, and unable to meet the demands of everyday life. If proven effective in a rigorously conducted multicenter randomized controlled trial (RCT), oral ketamine would provide an affordable and scalable, intervention suitable for integration into routine psychiatric services.This study will establish an indigenous, cost-effective therapeutic strategy that could improve accessibility, hasten therapeutic response, and inform treatment guidelines, if found to be safe and effective.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • HAM-D

    Measured over End of study week 3 (±2 days)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 65 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Consenting adult outpatients or inpatients with at least moderately severe major depressive episode (MDE), denoted by HAM- D more than or equal to 20, associated with major depressive disorder or bipolar disorder, with diagnosis confirmed using a structured diagnostic interview. Exclusion Criteria: * Patients with co-morbid obsessive-compulsive disorder or intellectual disability disorder or co-morbid substance dependence other than nicotine or patients concurrently receiving neuromodulation treatments or those with psychotic symptoms. Patients with current or ongoing suicide risk, such as active suicidal ideation with a specific plan or some intent in the last 3 days, will be excluded if they are treated as outpatients. Patients in whom, in the subjective opinion of the PI, the MDE symptoms appear to be significantly driven by acute life events or circumstances. Patients with abnormalities of concern detected in the electrocardiogram, or with uncontrolled hypertension or those with ongoing pregnancy or lactation

Where

5 study sites

FacilityCityRegionCountry
NIMHANSBangaloreKarnatakaIndia
Kasturba Medical CollegeUdupiKarnatakaIndia
MGM Medical College, MumbaiMumbaiMaharashtraIndia
AIIMS, BhubaneswarBhubaneswarOdishaIndia
Jawaharlal Institute of Postgraduate Medical Education and ResearchPuducherryPuducherryIndia

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07839338 on ClinicalTrials.gov →

Last updated in the registry 2026-09-24. Registry records change; this page reflects the data build of 2026-09-24.

Related

Where this trial sits